These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 6744243)
21. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro. Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001 [TBL] [Abstract][Full Text] [Related]
22. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity. Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831 [TBL] [Abstract][Full Text] [Related]
23. Suppression of Ehrlich ascites tumor growth in mice by starvation and streptozotocin-induced diabetes. Fung KP; Chan TW; Choy YM Cancer Lett; 1985 Sep; 28(3):273-80. PubMed ID: 3902210 [TBL] [Abstract][Full Text] [Related]
24. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358 [TBL] [Abstract][Full Text] [Related]
25. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892 [TBL] [Abstract][Full Text] [Related]
26. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers. Sharma A; Straubinger NL; Straubinger RM Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404 [TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of PALA in patients with refractory metastatic sarcomas. Kurzrock R; Yap BS; Plager C; Papdopoulos N; Benjamin RS; Valdivieso M; Bodey GP Am J Clin Oncol; 1984 Aug; 7(4):305-7. PubMed ID: 6741860 [TBL] [Abstract][Full Text] [Related]
28. Modulation of the activity of PALA by dipyridamole. Chan TC; Young B; King ME; Taetle R; Howell SB Cancer Treat Rep; 1985 Apr; 69(4):425-30. PubMed ID: 3857969 [TBL] [Abstract][Full Text] [Related]
29. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis. Moore EC Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357 [TBL] [Abstract][Full Text] [Related]
30. N-(Phosphonacetyl)-L-aspartate (PALA): current status. Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151 [TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine. Erlichman C; Vidgen D Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365 [TBL] [Abstract][Full Text] [Related]
32. Phase I trial of N-(phosphonacetyl)-L-aspartate. Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801 [TBL] [Abstract][Full Text] [Related]
33. Interrelationship of number of glucose carriers and intracellular phosphoribosyl diphosphate level of Ehrlich ascites tumor cells in vitro. Choy YM; Lam WP; Fung KP Cancer Biochem Biophys; 1988 Nov; 10(2):141-7. PubMed ID: 2472871 [TBL] [Abstract][Full Text] [Related]
34. Phase II trial of PALA in hypernephroma and urinary bladder cancer. Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651 [No Abstract] [Full Text] [Related]
35. m-AMSA and PALA: two new agents in cancer chemotherapy. Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427 [TBL] [Abstract][Full Text] [Related]
36. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue. Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903 [TBL] [Abstract][Full Text] [Related]
37. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells. Moyer JD; Smith PA; Levy EJ; Handschumacher RE Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293 [TBL] [Abstract][Full Text] [Related]
38. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration. Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806 [TBL] [Abstract][Full Text] [Related]
39. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man. Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467 [No Abstract] [Full Text] [Related]
40. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma. Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]